| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maurício Dos Santos Pereira, Gabriel Henrique Dias de Abreu, Leonardo Calaça Arruda Vanderlei, Rita Raisman-Vozari, Francisco Silveira Guimarães, Hui-Chen Lu, Patrick Pierre Michel, Elaine Del Be. 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms. Neuropharmacology. 2024-03-30. PMID:38554815. |
we tested the efficacy of 4'-fluorocannabidiol (4'-f-cbd), a semisynthetic cannabidiol derivative, and hu-910, a cannabinoid receptor 2 (cb2) agonist in resolving l-dopa-induced dyskinesia (lid). |
2024-03-30 |
2024-04-02 |
mouse |
| Andreza Buzolin Sonego, Douglas da Silva Prado, Francisco Silveira Guimarãe. PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. Progress in neuro-psychopharmacology & biological psychiatry. vol 111. 2021-11-11. PMID:34048863. |
a previous study showed that cannabidiol (cbd), the major non-psychotomimetic compound of cannabis sativa plant, prevents orofacial dyskinesia induced by typical antipsychotics by activating peroxisome proliferator-activated receptors gamma (pparγ). |
2021-11-11 |
2023-08-13 |
mouse |
| Andreza Buzolin Sonego, Douglas da Silva Prado, Francisco Silveira Guimarãe. PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. Progress in neuro-psychopharmacology & biological psychiatry. vol 111. 2021-11-11. PMID:34048863. |
pparγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. |
2021-11-11 |
2023-08-13 |
mouse |
| Nilson Carlos Ferreira Junior, Maurício Dos-Santos-Pereira, Francisco Silveira Guimarães, Elaine Del Be. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia. Neurotoxicity research. vol 37. issue 1. 2020-12-21. PMID:31637586. |
cannabidiol and cannabinoid compounds as potential strategies for treating parkinson's disease and l-dopa-induced dyskinesia. |
2020-12-21 |
2023-08-13 |
Not clear |
| Ricardo Plancarte-Sánchez, Armando Mansilla-Olivares, Víctor Alfonso De Los Reyes-Pacheco, Fernando Meneses-Gonzále. Aplicaciones terapéuticas por acción de los cannabinoides. Gaceta medica de Mexico. vol 155. issue 3. 2020-01-01. PMID:31219471. |
in recent years, studies have been conducted with cannabis in several diseases: controlled clinical trials on spasticity in multiple sclerosis and spinal cord injury, chronic, essentially neuropathic, pain, movement disorders (gilles de latourette, dystonia, levodopa dyskinesia), asthma and glaucoma, as well as non-controlled clinical trials on alzheimer's disease, neuroprotection, intractable hiccups, epilepsy, alcohol and opioid dependence and inflammatory processes. |
2020-01-01 |
2023-08-13 |
human |
| Maurício Dos-Santos-Pereira, Célia Aparecida da-Silva, Francisco Silveira Guimarães, Elaine Del-Be. Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action. Neurobiology of disease. vol 94. 2018-02-02. PMID:27373843. |
co-administration of cannabidiol and capsazepine reduces l-dopa-induced dyskinesia in mice: possible mechanism of action. |
2018-02-02 |
2023-08-13 |
mouse |
| Joseph W McSherr. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. vol 64. issue 6. 2006-02-22. PMID:15781848. |
cannabis for dyskinesia in parkinson disease: a randomized double-blind crossover study. |
2006-02-22 |
2023-08-12 |
Not clear |
| C B Carroll, P G Bain, L Teare, X Liu, C Joint, C Wroath, S G Parkin, P Fox, D Wright, J Hobart, J P Zajice. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. vol 63. issue 7. 2005-06-08. PMID:15477546. |
cannabis for dyskinesia in parkinson disease: a randomized double-blind crossover study. |
2005-06-08 |
2023-08-12 |
Not clear |
| C B Carroll, P G Bain, L Teare, X Liu, C Joint, C Wroath, S G Parkin, P Fox, D Wright, J Hobart, J P Zajice. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. vol 63. issue 7. 2005-06-08. PMID:15477546. |
the authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in pd. |
2005-06-08 |
2023-08-12 |
Not clear |